Cheng Liang, Poulos Christopher K, Pan Chong-Xian, Jones Timothy D, Daggy Joanne K, Eble John N, Koch Michael O
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, USA.
J Urol. 2005 Sep;174(3):898-902. doi: 10.1097/01.ju.0000169134.28610.66.
The detection of low volume and early stage prostate cancer has increased with the widespread use of prostate specific antigen screening for prostatic adenocarcinoma. This increased detection has led to efforts to stratify patient risk and the potential benefits of various treatments based on preoperative clinical and biopsy data. We examined various clinical parameters and prostate biopsy features to determine which variables are most predictive of small volume (less than 0.5 ml) cancer at prostatectomy.
We studied 336 patients who underwent prostatectomy for prostate cancer. Radical prostatectomy specimens were completely embedded and whole mounted. Final tumor volume in the radical prostatectomy specimens was determined by the grid method. Clinical data were gathered by a review of patient charts. Various preoperative clinical and biopsy findings were analyzed to determine factors predictive of small volume cancer at prostatectomy.
A total of 55 patients (16%) were found to have small volume cancer (less than 0.5 ml). On univariate logistic regression certain variables were significant predictors of small volume cancer, namely the highest Gleason score from all positive biopsy sites (p = 0.001), the Gleason score from the biopsy site with the highest percent of adenocarcinoma (p = 0.006), the highest percent of adenocarcinoma at any biopsy site (p <0.0001), the percent of adenocarcinoma at the biopsy site with the highest Gleason score (p <0.0001), the highest percent of cores positive for adenocarcinoma at any biopsy site (p = 0.001), the percent of cores with carcinoma at the site with the highest Gleason score (p = 0.002), the number of positive sites (p <0.0001) and tumor bilaterality (p <0.0001). None of the clinical parameters that we studied, including preoperative prostate specific antigen (p = 0.52), clinical stage (p = 0.62) or patient age (p = 0.94), was predictive of small volume cancer. On multivariate analysis the highest percent of adenocarcinoma at any site (adjusted OR 0.95, 95% CI 0.92 to 0.97, p <0.0001) and the number of positive biopsy sites (adjusted OR 0.97, 95% CI 0.96 to 0.99, p <0.0001) were significant predictors of small volume cancer.
The number of positive biopsy sites and the highest percent of adenocarcinoma at any biopsy site are significant predictors of small volume cancer in radical prostatectomy specimens.
随着前列腺特异性抗原筛查在前列腺腺癌中的广泛应用,小体积和早期前列腺癌的检出率有所增加。这种检出率的提高促使人们努力根据术前临床和活检数据对患者风险及各种治疗的潜在益处进行分层。我们研究了各种临床参数和前列腺活检特征,以确定哪些变量最能预测前列腺切除术中的小体积(小于0.5毫升)癌症。
我们研究了336例行前列腺癌前列腺切除术的患者。根治性前列腺切除标本被完全包埋并整体制片。根治性前列腺切除标本中的最终肿瘤体积通过网格法确定。通过查阅患者病历收集临床数据。分析各种术前临床和活检结果,以确定预测前列腺切除术中小体积癌症的因素。
共发现55例患者(16%)患有小体积癌症(小于0.5毫升)。在单因素逻辑回归分析中,某些变量是小体积癌症的显著预测因素,即所有阳性活检部位的最高Gleason评分(p = 0.001)、腺癌百分比最高的活检部位的Gleason评分(p = 0.006)、任何活检部位的最高腺癌百分比(p <0.0001)、Gleason评分最高的活检部位的腺癌百分比(p <0.0001)、任何活检部位腺癌阳性的最高芯数百分比(p = 0.001)、Gleason评分最高的部位有癌的芯数百分比(p = 0.002)、阳性部位数量(p <0.0001)和肿瘤双侧性(p <0.0001)。我们研究的所有临床参数,包括术前前列腺特异性抗原(p = 0.52)、临床分期(p = 0.62)或患者年龄(p = 0.94),均不能预测小体积癌症。在多因素分析中,任何部位的最高腺癌百分比(校正OR 0.95,95%CI 0.92至0.97,p <0.0001)和阳性活检部位数量(校正OR 0.97,95%CI 0.96至0.99,p <0.0001)是小体积癌症的显著预测因素。
阳性活检部位数量和任何活检部位的最高腺癌百分比是根治性前列腺切除标本中小体积癌症的显著预测因素。